Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).
Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglinas N, Low MS, Routledge D, Lim AB, Gibbs SD, Quach H, Morgan S, Moore E, Ninkovic S. Lim KJ, et al. Among authors: wellard c. EJHaem. 2023 Jul 25;4(3):639-646. doi: 10.1002/jha2.742. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601874 Free PMC article.
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators. Nguyen J, et al. Among authors: wellard c. Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915. Epub 2022 Dec 28. Eur J Haematol. 2023. PMID: 36539351
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).
Spencer A, Kalff A, Shortt J, Quach H, Wallington-Gates C, Reynolds J, Walker P, Harrison SJ, Dunn R, Wellard C. Spencer A, et al. Among authors: wellard c. Br J Haematol. 2023 Aug;202(4):801-811. doi: 10.1111/bjh.18955. Epub 2023 Jun 26. Br J Haematol. 2023. PMID: 37357593 Clinical Trial.
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).
Aoki N, Chen PY, Chen W, Chng WJ, Gan GG, Goh YT, Hou J, Huang J, Kim K, Lee JJ, Lu J, McQuilten ZK, Min CK, Moore E, Oliver L, Waters NA, Wellard C, Wood EM, Yeh SP, Spencer A; APAC MRDR Investigators. Aoki N, et al. Among authors: wellard c. BMC Med Res Methodol. 2024 May 2;24(1):102. doi: 10.1186/s12874-024-02227-0. BMC Med Res Methodol. 2024. PMID: 38698331 Free PMC article.
The cancer nursing workforce in Australia: a national survey exploring determinants of job satisfaction.
Bradford N, Moore E, Taylor K, Cook O, Gent L, Beane T, Williams N, Alexander K, Pitt E, Still J, Wellard C, McErlean G, Kirk D, Monterosso L, McCarthy A, Lokmic-Tomkins Z, Balson J, Gates P; CNSA Research Standing Committee; the CNSA Board of Directors. Bradford N, et al. Among authors: wellard c. BMC Nurs. 2023 Dec 6;22(1):461. doi: 10.1186/s12912-023-01629-7. BMC Nurs. 2023. PMID: 38057825 Free PMC article.
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry.
Nelson A, Ho PJ, Haysom H, Waters N, Wellard C, Chee M, Teo J, Greenway A, Mason K, Kidson-Gerber G, Kaplan Z, Carter T, Cole-Sinclair MF, Barbaro P, Wood EM; Haemoglobinopathy Registry investigators. Nelson A, et al. Among authors: wellard c. Intern Med J. 2024 May;54(5):764-772. doi: 10.1111/imj.16297. Epub 2023 Dec 8. Intern Med J. 2024. PMID: 38064543
Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage.
Caram-Deelder C, McKinnon Edwards H, Zdanowicz JA, van den Akker T, Birkegård C, Blatný J, van der Bom JG, Colucci G, van Duuren D, van Geloven N, Henriquez DDCA, Knight M, Korsholm L, Landorph A, Lavigne Lissalde G, McQuilten ZK, Surbek D, Wellard C, Wood EM, Mercier FJ. Caram-Deelder C, et al. Among authors: wellard c. J Clin Med. 2024 May 1;13(9):2656. doi: 10.3390/jcm13092656. J Clin Med. 2024. PMID: 38731185 Free PMC article.
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B, Chung E, Wellard C, Yoo E, Bennett R, Birks C, Johnston A, Cheah CY, Hamad N, Simpson J, Barraclough A, Ku M, Viiala N, Ratnasingam S, Armytage T, Cochrane T, Chong G, Lee D, Manos K, Keane C, Wallwork S, Opat S, Hawkes EA. Shaw B, et al. Among authors: wellard c. EJHaem. 2024 Feb 23;5(2):325-332. doi: 10.1002/jha2.870. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633125 Free PMC article.
36 results